Phase II Study of Peptide Cancer Vaccine S-488410 to Treat Advanced Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs S 488410 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 04 May 2012 Company (Shionogi) added as trial sponsor as reported by ClinicalTrials.gov.
- 04 May 2012 Planned end date Jun 2015 added as reported by ClinicalTrials.gov.